| 1 |
|
| 2 |
<p><b>NCE's in Development Phase</b></p> |
| 3 |
<p><b>PLD-116</b></p> |
| 4 |
<p>Approval of the German authorities was obtained to conduct the PLD-116 Phase |
| 5 |
I clinical study in Germany in December 2000. Prior to that, all the activities |
| 6 |
necessary to fulfill the requirements for the clinical testing of the compound |
| 7 |
had been undertaken and the pre-clinical testing completed. The PLD-116 project |
| 8 |
team has been established in December 1999, to develop peptide PL-10.1 into |
| 9 |
a drug for the treatment of inflammatory bowel disease. The peptide is derived |
| 10 |
from a natural protein and provides a novel anti-inflammatory treatment option |
| 11 |
for inflammatory bowel disease.</p> |
| 12 |
<p><b>PLD-117</b></p> |
| 13 |
<p>The peptide PLD-117 for the treatment of thrombocytopenia, a severe complication |
| 14 |
of cancer chemotherapy, was brought to clinical study trials in the USA in December |
| 15 |
2000. The proposed treatment is based on a unique approach using peptide that |
| 16 |
activates thrombopoietin (TPO) receptor. Prior to favourable communication from |
| 17 |
the FDA regarding the IND filling, and the evaluation of the clinical protocol, |
| 18 |
PLIVA has signed a licensing agreement with Receptron, Inc., a Californian based |
| 19 |
Biotech Company, and acquired exclusive rights to develop and market this possible |
| 20 |
new drug.</p> |
| 21 |
<p><b>PLD-118</b></p> |
| 22 |
<p>The licensed in novel antifungal agent PLD-118 was successfully brought into |
| 23 |
clinical development ahead of schedule in November 2000. PLD-118 has the potential |
| 24 |
to be the first novel oral antifungal for the treatment of Candida infections |
| 25 |
since the introduction of azoles in the 80's. After completing the preclinical |
| 26 |
package and successful review of necessary documents by the ethics committee |
| 27 |
in Germany, clinical studies started in November.</p> |
Parent Directory
| 
Revision Log